US EditionCutting-edge antibody therapy firm, AbCellera, to lay off 10 per cent of workforce
- AbCellera Biologics Inc. Has announced layoffs of 10% of its workforce, aiming to focus on developing new antibody medicines for COVID-19 patients.
- The company plans to incur approximately US$2.5 million in cash expense due to these layoffs.
- AbCellera had recently received significant funding to expand its Vancouver manufacturing plant for the production of antibodies and conduct clinical trials.
22 Articles
22 Articles
Cutting-edge antibody therapy firm, AbCellera, to lay off 10% of workforce
The Vancouver-based company that helped develop the first antibody therapy treatment for COVID-19 has announced layoffs amounting to 10 per cent of its workforce. AbCellera Biologics Inc., announced the cuts in a filing to the United States Securities and Exchange Commission. The filing says the lay...
Vancouver-based antibody therapy firm AbCellera to lay off 10% of workforce
The Vancouver-based company that helped develop the first antibody therapy treatment for COVID-19 announced Wednesday it was laying off 63 employees, but would still create and maintain more than 400 jobs in Canada.
Cutting-edge antibody therapy firm, AbCellera, to lay off 10 per cent of workforce
VANCOUVER — The Vancouver-based company that helped develop the first antibody therapy treatment for COVID-19 has announced layoffs amounting to 10 per cent of its workforce. AbCellera Biologics Inc.
Cutting-edge antibody therapy firm, AbCellera, to lay off 10 per cent of workforce
VANCOUVER — The Vancouver-based company that helped develop the first antibody therapy treatment for COVID-19 has announced layoffs amounting to 10 per cent of its workforce. AbCellera Biologics Inc.
Cutting-edge antibody therapy firm, AbCellera, to lay off 10 per cent of workforce
VANCOUVER — The Vancouver-based company that helped develop the first antibody therapy treatment for COVID-19 has announced layoffs amounting to 10 per cent of its workforce. AbCellera Biologics Inc.
Coverage Details
Bias Distribution
- 82% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
